Addex Therapeutics (ADXN) Cash & Current Investments (2018 - 2026)

Addex Therapeutics has reported Cash & Current Investments for 9 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Cash & Current Investments fell 62.0% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 62.0% YoY) and the FY2025 annual result came in at $2.0 million, down 47.91% from the prior year.
• Cash & Current Investments slipped to $1.2 million in Q1 2026 per ADXN's latest filing, from $2.1 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $16.1 million in Q1 2022 and troughed at $1.2 million in Q1 2026.
• A 5-year average of $5.5 million and a median of $4.2 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments tumbled 69.15% in 2024, then jumped 68.67% in 2025.
• Over 5 years, Cash & Current Investments stood at $7.2 million in 2022, then sank by 39.67% to $4.4 million in 2023, then dropped by 12.31% to $3.8 million in 2024, then plunged by 46.19% to $2.1 million in 2025, then slumped by 41.79% to $1.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $1.2 million, $2.1 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.